---
figid: PMC5784573__10.1177_1758834017742575-fig2
figtitle: 'Radiation effects on antitumor immune responses: current perspectives and
  challenges'
organisms:
- NA
pmcid: PMC5784573
filename: 10.1177_1758834017742575-fig2.jpg
figlink: /pmc/articles/PMC5784573/figure/fig2-1758834017742575/
number: F2
caption: Mechanistic changes in the antitumor immune response after radiotherapy.(I)
  RT triggers the recruitment of DCs to the tumor site by inducing adenosine triphosphate
  release.– Subsequently, calreticulin is translocated to the tumor cell surface,
  which triggers their phagocytosis., HMGB1 released after RT promotes processing
  and cross-presentation of tumor antigens taken up by DCs., Moreover, phagocytosis
  of irradiated tumor cells activates the cytosolic DNA sensing cGAS/STING pathway
  leading to the induction of IFN-β. This, together with complement activated by RT
  leads to DC maturation.– (II) DCs then migrate to the tumor-draining lymph nodes
  and prime CD8+ T cells,, which express high levels of PD-1, thus representing optimal
  targets for checkpoint inhibitors.,, In combination with IT, low-dose irradiation
  facilitates T-cell extravasation, which is mediated by iNOS+ macrophages and further
  perpetuated by the IFN-γ-dependent induction of adhesion molecules on the endothelium.,
  After RT alone, immunosuppressive CD11b+ cells are recruited from the bone marrow
  and drive tumor regrowth and vasculogenesis and in an MMP-9-dependent manner.– These
  CD11b+ myeloid cells are lured into the tumor tissue by radiation-induced CSF-1,
  CCL2 or CXCL12.,,– Of note, the TME after RT fosters the secretion of CXCL12 by
  TGF-β and NO-mediated upregulation of HIF-1α., In contrast to these immunosuppressive
  chemokines, CXCL16 and CXCL9/10 can attract cytotoxic T cells and thereby enhance
  IT efficacy.– (III) Once T cells activated by RT have infiltrated the tumor tissue,
  they encounter a heavily modified TME, which, in conjunction with IT, they can also
  modulate by killing immunosuppressive MDSCs by TNF-α or in a TCR-dependent manner.–
  Radiation induces a plethora of cytokines including type I and II IFNs, which, next
  to their already-discussed functions, can directly activate leukocytes and have
  direct cytotoxic effects on tumor cells.,, However, several immunosuppressive cytokines
  are released into the TME post-RT such as TGF-β and IL-6 leading to epithelial–mesenchymal
  transition, invasiveness and radioresistance.,, IT helps to shift the post-RT cytokine
  milieu towards antitumor immunity. RT also alters IT efficacy by quantitative and
  qualitative changes in tumor-infiltrating immunosuppressive leukocytes. CD11b+ myeloid
  cells expand due to CSF-1 induction and depending on radiation-dose macrophages,
  are skewed towards an M1- or M2-like phenotype, with the latter being sequestered
  in hypoxic areas.,,– In addition, Tregs accumulate due to priming by Langerhans
  cells and their intrinsic radioresistance., (IV) Finally, RT induces the expression
  of several molecules and receptors on the tumor cell surface, like MHC-I molecules,,
  TNFR superfamily members,– ATM-dependent induction of ligands for the NKG2D receptor–
  and calreticulin, leading to enhanced tumor cell killing by CD8+ T and NK cells.,,,
  However, RT can also induce excess levels of PD-L1 on tumor cells and thereby induce
  T-cell anergy underlining the rationale for combining RT and IT.,,,–ATM, ataxia
  teleangiectasia mutated; ATP, adenosine triphosphate; cGAS, cyclic GMP-AMP synthase;
  CCL, C-C motif chemokine ligand; CSF-1, colony stimulating factor-1; CXCL, C-X-C
  motif chemokine ligand; DC, dendritic cell; HIF-1α, hypoxia-inducible factor-1 alpha;
  HMGB1, high mobility group box 1; IFN, interferon; IL, interleukin; iNOS, nitric
  oxide synthase 2; IT, immunotherapy; LGP2, laboratories of genetics and physiology
  2; M1, M1-like macrophage (iNOShi, Arg1lo, Fizz-1lo); M2, M2-like macrophage (iNOSlo
  Arg1hi, Fizz-1lo) MDSC, myeloid-derived suppressor cell; MHC-I, major histocompatibility
  complex I; MMP-9, matrix metalloproteinase 9; NK, natural killer cell; NKG2D, killer
  cell lectin-like receptor K1; NO, nitric oxide; PD-1, programmed-cell-death 1; PD-L1,
  programmed-cell-death ligand 1, CD274 molecule; RT, radiotherapy; STING, transmembrane
  protein 173; TCR, T cell receptor; TGF-β, transforming growth-factor beta, TME,
  tumor microenvironment; TNF, tumor necrosis factor; TNFR, tumor necrosis factor
  receptor; Treg, regulatory T cell.
papertitle: 'Radiation effects on antitumor immune responses: current perspectives
  and challenges.'
reftext: Thomas Walle, et al. Ther Adv Med Oncol. 2018;10:1758834017742575.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9467708
figid_alias: PMC5784573__F2
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5784573__F2
ndex: 83a5d758-defc-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5784573__10.1177_1758834017742575-fig2.html
  '@type': Dataset
  description: Mechanistic changes in the antitumor immune response after radiotherapy.(I)
    RT triggers the recruitment of DCs to the tumor site by inducing adenosine triphosphate
    release.– Subsequently, calreticulin is translocated to the tumor cell surface,
    which triggers their phagocytosis., HMGB1 released after RT promotes processing
    and cross-presentation of tumor antigens taken up by DCs., Moreover, phagocytosis
    of irradiated tumor cells activates the cytosolic DNA sensing cGAS/STING pathway
    leading to the induction of IFN-β. This, together with complement activated by
    RT leads to DC maturation.– (II) DCs then migrate to the tumor-draining lymph
    nodes and prime CD8+ T cells,, which express high levels of PD-1, thus representing
    optimal targets for checkpoint inhibitors.,, In combination with IT, low-dose
    irradiation facilitates T-cell extravasation, which is mediated by iNOS+ macrophages
    and further perpetuated by the IFN-γ-dependent induction of adhesion molecules
    on the endothelium., After RT alone, immunosuppressive CD11b+ cells are recruited
    from the bone marrow and drive tumor regrowth and vasculogenesis and in an MMP-9-dependent
    manner.– These CD11b+ myeloid cells are lured into the tumor tissue by radiation-induced
    CSF-1, CCL2 or CXCL12.,,– Of note, the TME after RT fosters the secretion of CXCL12
    by TGF-β and NO-mediated upregulation of HIF-1α., In contrast to these immunosuppressive
    chemokines, CXCL16 and CXCL9/10 can attract cytotoxic T cells and thereby enhance
    IT efficacy.– (III) Once T cells activated by RT have infiltrated the tumor tissue,
    they encounter a heavily modified TME, which, in conjunction with IT, they can
    also modulate by killing immunosuppressive MDSCs by TNF-α or in a TCR-dependent
    manner.– Radiation induces a plethora of cytokines including type I and II IFNs,
    which, next to their already-discussed functions, can directly activate leukocytes
    and have direct cytotoxic effects on tumor cells.,, However, several immunosuppressive
    cytokines are released into the TME post-RT such as TGF-β and IL-6 leading to
    epithelial–mesenchymal transition, invasiveness and radioresistance.,, IT helps
    to shift the post-RT cytokine milieu towards antitumor immunity. RT also alters
    IT efficacy by quantitative and qualitative changes in tumor-infiltrating immunosuppressive
    leukocytes. CD11b+ myeloid cells expand due to CSF-1 induction and depending on
    radiation-dose macrophages, are skewed towards an M1- or M2-like phenotype, with
    the latter being sequestered in hypoxic areas.,,– In addition, Tregs accumulate
    due to priming by Langerhans cells and their intrinsic radioresistance., (IV)
    Finally, RT induces the expression of several molecules and receptors on the tumor
    cell surface, like MHC-I molecules,, TNFR superfamily members,– ATM-dependent
    induction of ligands for the NKG2D receptor– and calreticulin, leading to enhanced
    tumor cell killing by CD8+ T and NK cells.,,, However, RT can also induce excess
    levels of PD-L1 on tumor cells and thereby induce T-cell anergy underlining the
    rationale for combining RT and IT.,,,–ATM, ataxia teleangiectasia mutated; ATP,
    adenosine triphosphate; cGAS, cyclic GMP-AMP synthase; CCL, C-C motif chemokine
    ligand; CSF-1, colony stimulating factor-1; CXCL, C-X-C motif chemokine ligand;
    DC, dendritic cell; HIF-1α, hypoxia-inducible factor-1 alpha; HMGB1, high mobility
    group box 1; IFN, interferon; IL, interleukin; iNOS, nitric oxide synthase 2;
    IT, immunotherapy; LGP2, laboratories of genetics and physiology 2; M1, M1-like
    macrophage (iNOShi, Arg1lo, Fizz-1lo); M2, M2-like macrophage (iNOSlo Arg1hi,
    Fizz-1lo) MDSC, myeloid-derived suppressor cell; MHC-I, major histocompatibility
    complex I; MMP-9, matrix metalloproteinase 9; NK, natural killer cell; NKG2D,
    killer cell lectin-like receptor K1; NO, nitric oxide; PD-1, programmed-cell-death
    1; PD-L1, programmed-cell-death ligand 1, CD274 molecule; RT, radiotherapy; STING,
    transmembrane protein 173; TCR, T cell receptor; TGF-β, transforming growth-factor
    beta, TME, tumor microenvironment; TNF, tumor necrosis factor; TNFR, tumor necrosis
    factor receptor; Treg, regulatory T cell.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FASLG
  - FAS
  - FASN
  - STING1
  - ATP8A2
  - KLRK1
  - CGAS
  - ATM
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - IFNAR1
  - IFNAR2
  - HMGB1
  - IFNA1
  - C5AR1
  - C3AR1
  - TLR4
  - IFNB1
  - DHX58
  - CD86
  - CD80
  - ITK
  - SLC22A3
  - CD28
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - TLR1
  - ITGAM
  - CD8A
  - CD8B
  - TGFB1
  - TGFB2
  - TGFB3
  - IL6
  - CXCL16
  - CCL2
  - CSF1
  - ICAM1
  - VCAM1
  - TNF
  - NOS2
  - ISYNA1
  - C3
  - ERVK-2
  - C5
  - TCL1A
  - DCLK1
  - ADGRL1
  - CLU
  - AKR1C4
  - GZMB
  - POLR3K
  - ADGRL2
  - CCDC80
  - DCLK2
  - ERVW-5
  - NOS1
  - NOS3
  - ATP
  - TCR MHCH
  - TCR
  - cytotoxicity
---
